RIGI and cancer: Our previous data using an siRNA screen of Interferon-Stimulated Genes (ISGs) implicated LGP2 (DHX58), a member of the RLR pathway and suppressor of RIG-I/MDA5 signaling, as a key negative regulator of IR-induced IFN responses and thereby acts as a powerful radioprotector in multiple types of cancer cells and tumors [1].